0.00Open0.05Pre Close0 Volume695 Open Interest5.00Strike Price0.00Turnover1541.44%IV515.85%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1570Delta0.2568Gamma16.40Leverage Ratio-0.0430Theta0.0000Rho2.57Eff Leverage0.0001Vega
Assertio Stock Discussion
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study
Friday, 13th December at 8:00 am
LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced yesterday results of a clinical trial investigating the utility of Rolvedon® (eflapegrastim-x...
Underated/Valued, overlooked, great buy!!!
This one is killin it....
No comment yet